According to the new research report published by Precedence Research, titled “Autologous Cell Therapy Market (By Source: Epidermis, Bone Marrow, Mesenchymal Stem Cells, Haematopoietic Stem Cells, Chondrocytes, Others; By Application: Cancer, Cardiovascular Disorders, Neurodegenerative Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Others; By End-Use: Hospitals & Clinics, Ambulatory Centers, Academics & Research, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032 (By Product: Traditional, Advanced; By Application: Pottery, Tiles, Abrasives, Sanitary wave, Bricks & pipes, Others; By End User: Medical, Industrial, Building & Construction, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032”, the global autologous cell therapy market size is expected to be worth around US$ 38.24 billion by 2032 and is poised to record a yearly growth rate of 20.09% from 2023 to 2032. The study investigates several elements and their consequences on the growth of the all-wheel drive market.
This report focuses on autologous cell therapy market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall autologous cell therapy market size by analysing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2032. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2857
The study also provides important advancements in organic and inorganic growth strategies in the worldwide autologous cell therapy market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of autologous cell therapy market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.
Autologous Cell Therapy Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 7.36 Billion |
| Market Size by 2032 | USD 38.24 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 20.09% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Source, By Application, and By End-Use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Also read: Airless Packaging Market Size US$ 9.46 Billion by 2032
Market Key Players
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the autologous cell therapy market.
Some of the prominent players in the autologous cell therapy market include
- Autolus Therapeutics
- Lineage Cell Therapeutics, Inc.
- Sangamo Therapeutics
- Holostem Terapie Avanzate S.r.l.
- Vericel Corporation
- Opexa Therapeutics
- BrainStorm Cell Therapeutics
- Pharmicell Co., Inc.
- Bayer AG
- Daiichi Sankyo Co., Ltd
- Takeda Pharmaceutical Co., Ltd
- Sumitomo Chemical Co., Ltd
- Immuneel Therapeutics
- Lonza
Autologous Cell Therapy Market Segmentations
By Source
- Epidermis
- Bone Marrow
- Mesenchymal Stem Cells
- Haematopoietic Stem Cells
- Chondrocytes
- Others
By Application
- Cancer
- Cardiovascular Disorders
- Neurodegenerative Disorders
- Autoimmune Disorders
- Orthopedics
- Wound Healing
- Others
By End-Use
- Hospitals & Clinics
- Ambulatory Centers
- Academics & Research
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Report Objectives
- To define, segment, and project the global market size for autologous cell therapy market
- To understand the structure of the market by identifying its various sub-segments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyse the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
- To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
- To profile key players and comprehensively analyse their core competencies
- To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
- To analyse the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Autologous Cell Therapy Market
5.1. COVID-19 Landscape: Autologous Cell Therapy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Autologous Cell Therapy Market, By Source
8.1. Autologous Cell Therapy Market Revenue and Volume, by Source, 2023-2032
8.1.1 Epidermis
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Bone Marrow
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Mesenchymal Stem Cells
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Haematopoietic Stem Cells
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. Chondrocytes
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Autologous Cell Therapy Market, By Application
9.1. Autologous Cell Therapy Market Revenue and Volume, by Application, 2023-2032
9.1.1. Cancer
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Cardiovascular Disorders
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Neurodegenerative Disorders
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
9.1.4. Autoimmune Disorders
9.1.4.1. Market Revenue and Volume Forecast (2020-2032)
9.1.5. Orthopedics
9.1.5.1. Market Revenue and Volume Forecast (2020-2032)
9.1.6. Wound Healing
9.1.6.1. Market Revenue and Volume Forecast (2020-2032)
9.1.7. Others
9.1.7.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Autologous Cell Therapy Market, By End-Use
10.1. Autologous Cell Therapy Market Revenue and Volume, by End-Use, 2023-2032
10.1.1. Hospitals & Clinics
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Ambulatory Centers
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Academics & Research
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Autologous Cell Therapy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.1.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.2.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.6.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.7.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.3.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.6.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.7.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.6.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.7.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
Chapter 12. Company Profiles
12.1. Autolus Therapeutics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Lineage Cell Therapeutics, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sangamo Therapeutics
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Holostem Terapie Avanzate S.r.l.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Vericel Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Opexa Therapeutics
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. BrainStorm Cell Therapeutics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Pharmicell Co., Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Bayer AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Daiichi Sankyo Co., Ltd
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global autologous cell therapy market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for autologous cell therapy are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2023-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
